TRIM9 and myasthenia gravis: In our research, we found that in the PBMCs of MG patients and the serum of EAMG mice, the expression of miR-181a was downregulated, and the expression of TRIM9 was upregulated; the dual-luciferase report analyzed that miR-181a has a targeting relationship with TRIM9 and miR-181a can target the expression of TRIM9.